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Abstract. The stability of anti-malarial immunity will influence the interpretation of immunologic endpoints during
malaria vaccine trials conducted in endemic areas. Therefore, we evaluated cytokine responses to Plasmodium falci-
parum liver stage antigen-1 (LSA-1) and thrombospondin-related adhesive protein (TRAP) by Kenyans from a ho-
loendemic area at a 9-month interval. The proportion of adults with interferon- (IFN-) responses to 9-mer LSA-1
peptides was similar at both time-points, whereas responses from children decreased (P < 0.05). Response to the longer,
23-mer LSA-1 peptide was variable, decreasing in adults and children over time (P < 0.02 and P < 0.001, respectively).
The proportion of children with IFN- responses to either antigen at the second time-point was significantly lower than
that of adults, yet more adults responded to 9-mer TRAP peptides (P < 0.02). In contrast, the proportion of interleukin-
10 responses to LSA-1 and TRAP was similar at both time-points for both age groups. Most noteworthy was that even
when the repeat cross-sectional frequency of cytokine responses was the same, these responses were not generated by
the same individuals. This suggests that cytokine responses to LSA-1 and TRAP are transient under natural exposure
conditions.
INTRODUCTION
A major achievement in the fight against malaria will be the
development of a safe and efficacious vaccine that can be
delivered to infants and children living in malaria endemic
areas of the tropics. Evaluating clinical endpoints for vaccine
efficacy in this setting will be costly, time consuming, and
require large numbers of participants to achieve sufficient
power to detect differences in malaria-related morbidity be-
tween vaccinated and control groups.1,2 Identification and
validation of reliable immunologic correlates of protection
against infection and morbidity are therefore important goals
of malaria vaccine research.
The ongoing search for immune correlates of protection
against malaria includes characterizing T-cell responses to
malaria antigens that would prevent or diminish the intensity
and frequency of blood stage infection, the cause of clinical
illness such as fever and anemia. In the case of pre-
erythrocytic vaccine development, it has been shown that in-
oculation of malaria-naïve individuals with hundreds of irra-
diated sporozoites leads to complete protection against patent
blood stage infection after challenge with mosquitoes contain-
ing infective sporozoites. This immunity is transient and
wanes within several months.3 Observations of mouse malaria
models and of humans exposed to irradiated sporozoites in-
dicate that T-cell cytokine responses, particularly interferon-
(IFN-), are important in effecting and modulating this im-
munity that is largely directed against liver stage parasites.3–7
In contrast to the immunity elicited by large numbers of ir-
radiated sporozoites, the strength of the immune response
developed after repeated exposure to mosquito transmitted
infective sporozoites that characterizes natural immunity is
variable and less clearly associated with protection against
infection and morbidity. Complete protection against the pro-
gression of malaria parasites from the liver to blood stage
does not develop in the latter situation, although there is
evidence of an exposure- and age-related delay in time to
re-infection.8
Pre-erythrocytic Plasmodium falciparum vaccine candidate
antigens now or soon to undergo clinical trials in malaria
endemic areas include circumsporozoite antigen (CSP),9 liver
stage antigen-1 (LSA-1),10 and thrombospondin-related ad-
hesive protein (TRAP).11 LSA-1 is the only P. falciparum
antigen known to be expressed exclusively in hepatocytes.
CSP and TRAP are present on the surface of infective sporo-
zoites and are involved in the invasion of liver cells. T-cell
immunity to LSA-1 and TRAP is commonly observed in resi-
dents of malaria endemic areas, but the value and reproduc-
ibility of specific cytokine responses as correlates of protec-
tive immunity in this setting are not well established. For
example, some reports conclude that pre-existing IFN- re-
sponses to LSA-1 are predictive of delayed time to re-
infection or a lower rate of blood stage infection, whereas
others show no correlation.12–15 Similarly, LSA-1–driven IL-
10 responses have been suggested to be predictive of resis-
tance to re-infection.16 Flanagan and others17 reported that
the overall frequency of ex vivo IFN- responses to 14 over-
lapping TRAP peptides was 40% of 217 donors living in
Kilifi, Kenya. The response rates diminished from 70% to
36% in a subset of 69 individuals selected for re-testing 1 year
after the initial examination. Factors contributing to the ap-
parent variability of T-cell cytokine responses include the age
of the individuals examined, recent or current exposure to
sporozoites, the presence of blood stage infection, treatment
with anti-malarial drugs, the specific cytokines selected for
study, and the stability of immune responses over time. To
address these gaps in knowledge, we conducted a study of
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adults and children living in a malaria holoendemic area of
western Kenya during two consecutive seasons of differing
transmission. LSA-1– and TRAP-driven IFN- and interleu-
kin-10 (IL-10) responses were evaluated for population
prevalence and concordance over the 9-month period.
MATERIALS AND METHODS
Ethical review and informed consent. This study was ap-
proved by the Ethical Review Committee of the Kenya Medi-
cal Research Institute and the Institutional Review Board for
Human Studies at University Hospitals of Cleveland, Case
Western Reserve University. Written informed consent was
obtained from all participants 18 years old and from guard-
ians of participants <18 years old.
Study site and repeated cross-sectional study design. Par-
ticipants were recruited from the Kanyawegi sub-location in
Kisumu District, Nyanza Province, Kenya. Malaria transmis-
sion in this area is high (annual entomological inoculation
rates can exceed 300 infectious bites per person) with sea-
sonal variation.18 Immunologic measurements reported here
were performed two times over a 9-month interval. The first
measurement was in November 2000 when the monthly en-
tomological inoculation rate was estimated to be three infec-
tious bites per person. The second immunologic measurement
was performed in August 2001 when the monthly entomo-
logical inoculation rate was estimated to be 3- to 4-fold higher
(Kim Lindblade, personal communication).
Blood sample collection and processing. Adults (18
years) donated 12–16 mL blood and children (2–9 years) do-
nated 5–8 mL blood collected in sodium heparin tubes.
Samples were transported at room temperature to the labo-
ratory for processing. Peripheral blood mononuclear cells
(PBMCs) were isolated by Ficoll-Hypaque density centrifu-
gation and resuspended in complete RPMI containing 10%
human AB serum, 10 mmol/L L-glutamine, and 10 g/mL
gentamicin. Typical yields were 2 × 106 PBMC/mL blood
from children and 1 × 106 PBMC/mL blood from adults. Suf-
ficient PBMCs for cytokine analyses were obtained from 93
adults and 66 children during the first collection and 114
adults and 119 children during the second collection. Fifty-
four adults and 59 children donated blood at both time-
points. The study population was 48% female. Exclusion cri-
teria included pregnancy and self-reported treatment of ma-
laria 2 weeks before blood collection.
LSA-1 and TRAP peptides. LSA-1 and TRAP peptides
used for the study are listed in Table 1. These peptides have
been shown to elicit T-cell responses in Africans naturally
exposed to malaria17,19,20 and were based on the major his-
tocompatibility complex (MHC) Class 1 types present in our
study population.21 Long and short peptides from LSA-1 and
TRAP were synthesized and purified to >95% by high-
performance liquid chromatography (Sigma Genosys,
Gainesville, TX).
IFN- ELISPOT and IL-10 ELISA. For IFN- ELISPOT
assays, PBMCs were plated at 0.5 × 106 cells/well in Millipore
MAIP ELISPOT 96-well microtiter plates (Millipore Corp.,
Billerica, MA) pre-coated at 4°C overnight with 5 g/mL
human anti-IFN- monoclonal antibodies (Endogen M-700A,
Rockford, IL), washed with sterile phosphate-buffered saline
(PBS), pH 7.4, and blocked with 10% heat-inactivated fetal
bovine serum in PBS. PBMC were incubated at 37°C in 5%
CO2 for 5 days in culture medium alone (negative control), 10
g/mL malaria peptide, and 1 g/mL phytohemagglutinin
(PHA; positive control). Details of subsequent steps and enu-
meration of spot forming units (SFUs)/106 PBMCs are as
described.13 For IL-10 assays, PBMC were plated at 0.2 × 106
cells/well in sterile U-bottom polystyrene microtiter plates
(Falcon 35-3077; Becton Dickinson & Co, Franklin Lakes,
NJ) and incubated with malaria peptides, PHA, or PBS alone
for 5 days as described for the IFN- ELISPOT. Supernatants
were kept frozen at −20°C until IL-10 ELISAs were per-
formed.14
Malaria peptides were tested under the same incubation
conditions using PBMCs obtained from 20 healthy malaria-
naïve controls from Cleveland, OH. A pool of EBV peptides
was used as positive 9-mer peptide controls. Positive re-
sponses to the EBV peptides were observed in the both the
malaria exposed and malaria-naïve donors (data not shown).
Malaria-naïve volunteers had no detectable IFN- ELISPOT
responses to any of the malaria peptides. A positive IL-10
response by a study participant was scored if the value was
greater than 2 SD above the mean of the 20 control malaria-
naïve blood donors. IL-10 cut-off values for the various pep-
tides were as follows: 20 pg/mL for T3, 85 pg/mL for ls84, 43
pg/mL for ls94, 51 pg/mL for ls1881, and 20 pg/mL for tr539,
tr51, and tr6.
Malaria infection and surveillance for clinical malaria. Ma-
laria infection was determined by microscopic inspection of
blood smears. Parasitemia was quantified by counting the
number of asexual parasites observed after visualizing at least
200 leukocytes. Densities were calculated assuming a leuko-
cyte count of 8,000/L blood. Beginning in January 2001,
study participants enrolled in immunologic studies in Novem-
ber 2000 were visited weekly by trained field assistants and
queried about signs and symptoms of malaria.13 Participants
contacted their village field assistant if they had fever, chills,
headache, or severe malaise. Clinical malaria was defined as
the presence of any of these symptoms with 4,000 parasites/
L blood. Individuals with clinical malaria were treated with
sulfadoxine-pyrimethamine (the drug recommended by the
Kenya Ministry of Health for treatment of uncomplicated
malaria at the time) unless allergic to this medication, in
which case they were given amodiaquine or quinine.
Statistical analysis. An IFN- ELISPOT was considered
positive if the proportion of SFUs in the stimulated well was
significantly greater compared with the unstimulated back-
ground well (P < 0.05). The significance test was a 2 com-
TABLE 1
LSA-1 and TRAP peptides used for this study
Malaria antigen
(amino acid position*) Amino acid sequence Abbreviation
LSA-1 (84–92) LPM SNV KNV ls84
LSA-1 (94–102) QTN FKS LLR ls94
LSA-1 (1881–1889) LFH IFD GDN ls1881
LSA-1 (1813–1835) NEN LDD LDE GIE KSS
EEL SEE KI
T3
TRAP (51–59) LLM DCS GSI tr51
TRAP (539–547) TPY AGE PAP tr539
TRAP (51–70) LLM DCS GSI RRH NWV
NHA VP
tp6
* Numbers represent amino acid position based on NCBI GenBank Entrez accession no.
CAA39663 for LSA-1 and A46283 for TRAP.
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parison of two proportions adjusting for small sample size and
assuming a Poisson distribution. An IL-10 ELISA response
was considered positive if it was greater than the cut-off value
based on the malaria-naïve negative control studies as de-
scribed above. A 2 test of homogeneity was used to deter-
mine whether the proportion of children with IFN- and IL-
10 responses were significantly different than that of the
adults. A two-sided Wilcoxon (Mann-Whitney) rank sum test
was used to determine whether one group had a lower IFN-
precursor frequency or lower mean IL-10 response than an-
other group. The correlation between responses to both cy-
tokines was assessed by Spearman rank test. A 2 test of
homogeneity was used to determine whether the proportion
of individuals with cytokine responses was significantly dif-
ferent between time-points. All analyses were conducted in
SAS version 8.2 (SAS, Cary, NC).
RESULTS
Proportion of IFN- and IL-10 responders comparing chil-
dren to adults at two times. Eighty-six adults and 59 children
from the first collection in November 2000 and 93 adults and
96 children from the second collection in August 2001 had
interpretable IFN- ELISPOT results. Data from the first
collection showed no significant differences for the propor-
tion of responders when children were compared with adults
for any of the peptides assayed (e.g., 16–29% in each age
group responded to one or more of the LSA-1 peptides and
14–22% to the TRAP peptides; Table 2). Nine months later,
however, fewer children than adults responded. This was true
for all of the peptides tested at both time-points (e.g., PBMCs
from 7 of 96 [7%] children versus 38 of 92 [41%] adults made
IFN- when stimulated with the tr6 peptide; P  0.001).
The pattern of IL-10 responses differed from IFN-. First,
the proportion of individuals responding to any of the pep-
tides was lower regardless of age or the time of blood collec-
tion (i.e., the range of IL-10 response rates for children was
0–19% [N 27–74] and 9–32% [N 39–74] for adults; Table
3). Second, with the exception of one TRAP peptide (tr539),
the frequency of IL-10 responses was not significantly differ-
ent for children compared with adults at either time-point.
There was no correlation between IFN- and IL-10 responses
for any of the peptides (results not shown).
To determine if there was a difference in the magnitude of
cytokine responses between adults and children over the
9-month study period, data for all persons with detectable
cytokine responses were compared. The range for IFN- re-
sponses detected by ELISPOT for any malaria peptide was
30–200 SFU/106 PBMCs with no significant difference (P >
0.1) among the seven peptides tested. The magnitude of re-
sponse did not significantly differ by age or time of collection
(data not shown). Similarly for IL-10, the amount of cytokine
produced did not differ significantly according to malaria pep-
tide, age, or time of collection (data not shown). The range of
IL-10 responses to the various malaria peptides was 90–200
pg/mL.
Stability of cytokine responses for individuals examined at
both time-points. Samples from the same individuals were ob-
tained at both collection periods from 54 adults and 59 chil-
dren. Comparison of cytokine responses was determined us-
ing IFN- ELISPOT results for adults only because the repeat
cross-sectional frequency of responders was the same,
whereas responses from the children showed an overall de-
crease from November 2000 to August 2001 (Table 2). There
were too few individuals who had IL-10 responses to make
meaningful comparisons (Table 3). For this analysis, an indi-
vidual’s peptide-specific immune response was categorized as
“stable” if IFN- was detected at both time-points, “lost” if
positive at the first and negative at the second collection,
“gained” if negative at the first and positive at the second
collection, and “non-responsive” if negative at both time-
points. These data are summarized in Table 4. First, we ob-
served that the proportion of persons with “stable” responses
was low regardless of the peptide tested. The peptide that
most consistently stimulated an IFN- response was ls1881,
but this was found in only 6 of 43 (14%) individuals. Second,
“loss” or “gain” of responses between the first and second
time of PBMC collection was observed in a greater propor-
tion of individuals (the range for persons in these categories
was 7–36%). None of the LSA-1 or TRAP peptides stood out
as being associated with either category, possibly with excep-
tion of responses to LSA-1 T3, which were “lost” by 15 of 47
(32%) participants and tr539 and tr51, which were “gained”
by 16 of 44 (36%) individuals. The most common category
was “non-responders,” which varied from 42% of participants
for ls1881 to 62% of participants for ls84.
Relationship of P. falciparum parasitemia, symptomatic
malaria, and anti-malarial drugs to cytokine responses. The
TABLE 2
Repeat cross-sectional proportions of children and adults with IFN-
ELISPOT responses to LSA-1 and TRAP
Age group comparisons
LSA-1 peptides
ls84 % children (N) % adults (N) P value
Nov. 2000 24% (13/55) 23% (20/86) 0.958
Aug. 2001 4% (3/84) 18% (17/93) 0.002*
P value 0.001* 0.411
ls94 % children (N) % adults (N) P value
Nov. 2000 16% (9/55) 26% (22/86) 0.197
Aug. 2001 6% (6/96) 27% (25/92) 0.001*
P value 0.048 0.810
ls881 % children (N) % adults (N) P value
Nov. 2000 24% (12/49) 24% (21/86) 0.993
Aug. 2001 ND 37% (31/83) ND
P value ND 0.069
T3 % children (N) % adults (N) P value
Nov. 2000 25% (15/59) 29% (26/86) 0.629
Aug. 2001 5% (5/96) 15% (14/93) 0.026
P value 0.001* 0.023*
TRAP peptides
tr539 % children (N) % adults (N) P value
Nov. 2000 20% (9/44) 22% (18/83) 0.872
Aug. 2001 ND 38% (30/79) ND
P value ND 0.023*
tr51 % children (N) % adults (N) P value
Nov. 2000 14% (6/42) 16% (13/83) 0.839
Aug. 2001 8% (8/96) 39% (36/92) 0.001*
P value 0.292 0.001*
tp6 % children (N) % adults (N) P value
Nov. 2000 ND ND ND
Aug. 2001 7% (7/96) 41% (38/92) 0.001*
P value ND ND
* Significant P value < 0.05.
ND, not done.
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prevalence of blood stage infection was 61% (57/93) in adults
and 91% (60/66) in children when the first immunologic study
was performed in November 2000. Mean parasite densities
were 636 and 6615 parasites per microliter for adults and
children, respectively. At the time of the second collection in
August 2001, 51% (58/114) of adults (mean parasite density,
410/L) and 78% (93/119) of children (mean parasite density,
4,969/L) had blood stage infection. The difference in para-
site prevalence between time-points was significant for chil-
dren (P  0.028) but not for adults (P  0.13). Gametocyte
rates were lower (P 0.01) in children over time, decreasing
from 29% (19/66) to 13% (16/119). Five adults met the diag-
nostic criteria for clinical malaria at the time of blood collec-
tion and received anti-malarial treatment. Children were
more likely to be symptomatic with P. falciparum parasitemia
at the two cross-sectional surveys, 37% (22/59) and 28% (27/
96) in November 2000 and August 2001, respectively, and
were treated with sulfadoxine-pyrimethamine. Active surveil-
lance for clinical malaria began immediately after the first
immunologic measurement was performed. Forty-nine per-
cent (58/119) of children had a symptomatic malaria episode
during the 9-month study period and were treated with anti-
malarial drugs. IFN- or IL-10 responses were not associated
with prior or concurrent parasitemia (both children and
adults) or prior and concurrent treatment of symptomatic ma-
laria (children only).
DISCUSSION
Studies of malaria-naïve humans and rodents immunized
with pre-erythrocytic malaria vaccine antigens have shown
that malaria-specific T-cell IFN- responses are closely linked
with protection against challenge infection.3,5–7 In contrast,
T-cell responses to the same antigens by persons with immu-
nity resulting from repeated exposures to mosquito-borne
sporozoites differ substantially. This is evident by less vigor-
ous and more complex responses that include IFN-, IL-10,
and tumor necrosis factor- and a weak association with pro-
tection when measured as time to re-infection.14,22 Apprecia-
tion of this variability in background T-cell responses will be
important for malaria vaccine development in endemic popu-
lations where immune correlates may serve as primary end-
points for immunogenicity and secondary endpoints for para-
sitological or clinical efficacy. To understand better the sta-
bility of T-cell cytokine responses to LSA-1 and TRAP in
target populations for malaria vaccine testing, we assessed
IFN- and IL-10 responses to LSA-1 and TRAP peptides at
two time-points over a 9-month interval in children and adults
living in a malaria holoendemic area of western Kenya. We
found that the proportion of children and adults with IFN-
responses far exceeded those with IL-10. Additionally, IFN-
and IL-10 responses were not concordant, and IFN- re-
sponses by adults were not stable over time. Temporal
changes in population and individual T-cell responses did not
correlate with the presence of blood stage infection, transmis-
sion as estimated by entomologic inoculation rate, symptom-
atic malaria, or treatment with anti-malaria drugs.
The impact of malaria transmission on the acquisition and
maintenance of T-cell responses to the antigens studied here
has to date not been well characterized. An earlier study we
conducted in the highlands of western Kenya suggested that
IL-10 responses to LSA-1 correlated with protection against
infection that was evident between the rainy and dry seasons,
whereas IFN- responses were unchanged.23 In contrast to
the high endemicity in the region where this study was done,
malaria transmission in the highlands of western Kenya is
sporadic, with long intervening periods of low or absent blood
stage infection. Taken together, these data suggest that the
pattern of exposure to sporozoites qualitatively influences im-
munity to pre-erythrocytic antigens, such that during periods
of low transmission, maintenance of IL-10 responses is fa-
vored, whereas high levels of exposure shift the response to-
ward IFN-. This hypothesis is supported by observations
comparing children with severe versus mild malaria in Gabon.
IL-10 responses were associated with lower parasite densities
in mild malaria cases and correlated inversely with severe
malaria and high-density parasitemia.15
Few other studies have addressed the stability of T-cell
cytokine responses to pre-erythrocytic malaria antigens. A
repeat cross-sectional study by Kurtis and others24 of adult
Kenyans living in a malaria holoendemic area near the study
site described here supports the notion that LSA-1–driven
IFN- responses are unstable. In contrast with our results,
these workers observed that the frequency of responses to
LSA-1 was greater rather than less during the period of high
than low transmission. The apparent lack of stability of IFN-
responses reported here may be explained by several possible
mechanisms. First, if T-cell responses to LSA-1 and TRAP
are short-lived and depend on recent exposure to liver stage
TABLE 3
Repeat cross-sectional proportions of children and adults with IL-10
ELISA responses to LSA-1 and TRAP
Age group comparisons
LSA-1 peptides
ls84 % children (N) % adults (N) P value
Nov. 2000 6% (2/36) 16% (7/48) 0.135
Aug. 2001 10% (5/48) 25% (11/44) 0.065
P value 0.425 0.315
ls94 % children (N) % adults (N) P value
Nov. 2000 6% (2/34) 17% (7/42) 0.148
Aug. 2001 19% (14/73) 13% (6/46) 0.383
P value 0.073 0.632
ls881 % children (N) % adults (N) P value
Nov. 2000 3% (1/31) 10% (4/41) 0.280
Aug. 2001 ND 16% (5/31)
P value 0.418
T3 % children (N) % adults (N) P value
Nov. 2000 6% (2/35) 9% (4/43) 0.554
Aug. 2001 19% (14/74) 21% (10/47) 0.751
P value 0.069 0.117
TRAP peptides
tr539 % children (N) % adults (N) P value
Nov. 2000 0% (0/27) 28% (11/39) 0.003*
Aug. 2001 ND 32% (10/31)
P value 0.713
tr51 % children (N) % adults (N) P value
Nov. 2000 ND ND
Aug. 2001 14% (10/73) 19% (9/47) 0.425
P value
tp6 % children (N) % adults (N) P value
Nov. 2000 ND ND
Aug. 2001 10% (7/69) 15% (7/47) 0.441
P value
* Significant P value < 0.05.
ND, not done.
MOORMANN AND OTHERS588
P. falciparum, it is possible that antigenic polymorphism may
contribute to the gain, loss, or lack of responses during the
first and second collection periods. Polymorphisms in the re-
gion of the LSA-1 gene corresponding to ls84 have been ob-
served, whereas the gene sequences corresponding to the
TRAP peptides we used for our study are believed to be
relatively conserved.17,25,26 Second, co-existing blood stage
infection could suppress pre-erythrocytic immunity through
inhibition of dendritic cell functions such as antigen process-
ing or expression of costimulatory molecules.27–29 We have
not examined whether this mechanism is operative but note
the lack of correlation of IFN- responses with concurrent
blood stage infection and parasite density. Third, sampling of
T-cell populations with specificity for liver stage malaria an-
tigens may be limited by the ability to detect such cells in the
peripheral circulation, especially in persons who are naturally
infected and presumably have few viable liver stage P. falci-
parum present at one time. In this context, mouse malaria
models suggest that T cells with specificity for hepatic stage
malaria may be preferentially localized in the liver.30 It is
noteworthy that T-cell cytokine responses to vaccine candi-
dates that include the TRAP peptides studied here are readily
detectable in the peripheral blood of malaria-naïve humans
after administration of experimental vaccines by prime boost
strategies such as plasmid DNA followed by recombinant
non-replicating poxviruses.31,32
Continuing study of the persistence and stability of effector
and memory T cells with specificity for pre-erythrocytic anti-
gens is warranted if the goal of defining reproducible immune
correlates of protection is to be achieved. We believe that
such studies should include comparison of the levels of total
and antigen-specific CD4 and CD8 T cell subsets responses
over shorter periods of time (e.g., at 1- or 2-week intervals),
so that limitations of interpretation related to temporal sta-
bility can be limited by excluding changes in transmission
intensity and other variables such as exposure to other infec-
tious pathogens. Such work will ultimately be useful in un-
derstanding whether the apparent lack of long-term memory
in human falciparum malaria is related to T-cell attrition and
apoptosis.33–35 A better understanding of whether and how
T-cell memory to malaria develops in humans will hopefully
lead to rational strategies for boosting and maintaining the
immunity elicited by a malaria vaccine.
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